These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 512353)

  • 21. Antibody response to rubella virion (V) and soluble (S) antigens in rubella infection and following vaccination with live attenuated rubella virus.
    Vesikari T; Vaheri A; Leinikki P
    Arch Gesamte Virusforsch; 1971; 35(1):25-37. PubMed ID: 4943281
    [No Abstract]   [Full Text] [Related]  

  • 22. Neutralizing antibodies after rubella vaccination of newly delivered women: a comparison between three vaccines.
    Grillner L
    Scand J Infect Dis; 1975; 7(3):169-72. PubMed ID: 1237176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical manifestations, according to age, among females given HPV-77 duck rubella vaccine.
    Swartz TA; Klingberg W; Goldwasser RA; Klingberg MA; Goldblum N; Hilleman MR
    Am J Epidemiol; 1971 Sep; 94(3):246-51. PubMed ID: 5093654
    [No Abstract]   [Full Text] [Related]  

  • 24. Neutralizing and hemagglutination-inhibiting antibodies to rubella virus as indicators of protective immunity in vaccinees and naturally immune individuals.
    Schluederberg A; Horstmann DM; Andiman WA; Randolph MF
    J Infect Dis; 1978 Dec; 138(6):877-83. PubMed ID: 105058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomised double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women.
    Tingle AJ; Mitchell LA; Grace M; Middleton P; Mathias R; MacWilliam L; Chalmers A
    Lancet; 1997 May; 349(9061):1277-81. PubMed ID: 9142061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study of young women vaccinated against rubella virus for 10 years in Taiwan.
    Lin DB; Kao CL; Lee CY
    Southeast Asian J Trop Med Public Health; 1996 Dec; 27(4):707-14. PubMed ID: 9253871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trials with a live attenuated rubella virus vaccine, Cendehill strain.
    Grant L; Belle EA; Provan G; King SD; Sigel MM
    J Hyg (Lond); 1970 Sep; 68(3):505-10. PubMed ID: 5272349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistence of antibody after subcutaneous vaccination with Wistar RA27/3 rubella vaccine.
    Hillary IB
    J Hyg (Lond); 1971 Sep; 69(3):369-72. PubMed ID: 5285940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rubella vaccination in Australia: 2. Experience with the RA27/3 rubella vaccine and results of a double-blind trial in schoolgirls.
    Menser MA; Forrest JM; Bransby RD; Collins E
    Med J Aust; 1978 Jul; 2(3):85-8. PubMed ID: 362141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Wistar RA27/3 rubella virus vaccine in children.
    Balfour HH; Balfour CL; Edelman CK; Rierson PA
    Am J Dis Child; 1976 Oct; 130(10):1089-91. PubMed ID: 973611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA-DR antigens and the rubella-specific immune response in man.
    Kato S; Muranaka S; Takakura I; Kimura M; Tsuji K
    Tissue Antigens; 1982 Feb; 19(2):140-5. PubMed ID: 6808699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunity to intranasal challenge with Rubella virus two years after vaccination: comparison of three vaccines.
    Grillner L
    J Infect Dis; 1976 Jun; 133(6):637-41. PubMed ID: 932491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Vaccination of adult women with Cendehill anti-rubella vaccine. Controlled experiments and review of the literature].
    Gold JA
    Minerva Med; 1970 Apr; 61(30 Suppl):1599-1600. PubMed ID: 5439725
    [No Abstract]   [Full Text] [Related]  

  • 34. Study of the teratogenicity of the vaccine strain of the Rubella virus «Orlov-V» (Matonaviridae: Rubivirus: Rubella virus) in experience on rhesus macaques.
    Lavrentjeva IN; Shamsutdinova OA; Chugueva II; Karal-Ogly DD; Vyshemirskiy OI
    Vopr Virusol; 2021 Jan; 65(6):357-363. PubMed ID: 33533577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical laboratory evaluation of rubella virus vaccine given to postpartum women without pregnancy preventive.
    Villarejos VM; Arguedas JA; Hernandez GC; Buynak EB; Hilleman MR
    Obstet Gynecol; 1973 Nov; 42(5):689-95. PubMed ID: 4749573
    [No Abstract]   [Full Text] [Related]  

  • 36. Vaccination of schoolgirls against rubella. Assessment of serological status and a comparative trial of Wistar RA 27/3 and Cendehill strain live attenuated rubella vaccines in 13-year-old schoolgirls in Dudley.
    Freestone DS; Reynolds GM; McKinnon JA; Prydie J
    Br J Prev Soc Med; 1975 Dec; 29(4):258-61. PubMed ID: 766879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and reactogenicity of live attenuated rubella virus vaccines.
    Andzhaparidze OG; Desyatskova RG; Chervonski GI; Pryanichnikova LV
    Am J Epidemiol; 1970 May; 91(5):527-30. PubMed ID: 5462118
    [No Abstract]   [Full Text] [Related]  

  • 38. The immunoglobulin M response to rubella vaccine in young adult women.
    Mortimer PP; Edwards JM; Porter AD; Tedder RS; Haslehurst J
    J Hyg (Lond); 1984 Jun; 92(3):277-83. PubMed ID: 6376624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gestational exposure to rubella vaccinees: a population surveillance study.
    Fleet WF; Vaughn W; Lefkowitz LB; Schaffner W; Federspiel CF
    Am J Epidemiol; 1975 Mar; 101(3):220-30. PubMed ID: 1115060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Investigations on the dependency of hemagglutination inhibition titers against rubella virus on the number and quality of antibody molecules (author's transl)].
    Hoppe G
    Zentralbl Bakteriol A; 1981; 249(2):143-51. PubMed ID: 7269848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.